Prelude Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Prelude Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$573K	Sell	121,912 -84,614	-41%	-$429K	0.04%	458
2025 Q4	$880K	Hold	206,526	–	–	0.06%	355
2025 Q3	$659K	Buy	+206,526	New	+$465K	0.05%	428
2020 Q4	–	Sell	-1,700	Closed	-$11K	–	1400
2020 Q3	$11K	Buy	1,700 +1,300	+325%	+$9.64K	﹤0.01%	1439
2020 Q2	$3K	Buy	+400	New	+$3.71K	﹤0.01%	1778
2019 Q3	–	Sell	-611	Closed	-$7K	–	1762
2019 Q2	$7K	Buy	+611	New	+$6.41K	﹤0.01%	1456
2018 Q4	–	Sell	-72	Closed	-$1K	–	1837
2018 Q3	$1K	Sell	72 -10,385	-99%	-$237K	﹤0.01%	1682
2018 Q2	$239K	Buy	10,457 +9,254	+769%	+$236K	0.02%	713
2018 Q1	$34K	Buy	1,203 +802	+200%	+$22.9K	﹤0.01%	1178
2017 Q4	$8K	Buy	+401	New	+$8.31K	﹤0.01%	1229
2017 Q3	–	Sell	-300	Closed	-$5K	–	1669
2017 Q2	$5K	Buy	+300	New	+$4.52K	﹤0.01%	1464

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prelude Capital Management's CTMX Position: Q1 2026 in Review

Prelude Capital Management reduced its CytomX Therapeutics (CTMX) stake by 41% in Q1 2026, selling an estimated $429K and leaving 121,912 shares worth $573K. The position accounts for 0.04% of the portfolio, ranked #458.

Prelude Capital Management first reported a position in CTMX in Q2 2017 and has held it in 11 quarters since. The position peaked at $880K in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

Prelude Capital Management held 121,912 shares of CytomX Therapeutics worth $573K as of Q1 2026.
Prelude Capital Management sold 84,614 CytomX Therapeutics shares in Q1 2026, an estimated $429K.
CytomX Therapeutics made up 0.04% of Prelude Capital Management's portfolio in Q1 2026, its #458 holding.
Prelude Capital Management first reported a position in CytomX Therapeutics in Q2 2017 and has held it in 11 quarters since.
Prelude Capital Management's CytomX Therapeutics position peaked at $880K in Q4 2025.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.